Stock Events

Stock Events

Apollomics

$28.01

26

+$0.66+2.43% Thursday 20:00

-$0.24-0.86%Thursday 23:30After hours

Statistics

Day High

27.5

Day Low

27.5

52W High

42.12

52W Low

4.21

Volume

1,034

Avg. Volume

-

Mkt Cap

81.12M

P/E Ratio

-

Dividend Yield

-

Dividend

-

Upcoming

Earnings

24SepExpected

Q4 2023

Q2 2024

Q1 2025

Q2 2025

Q3 2025

Q1 2026

Next

-24

-23.67

-23.33

-23

Expected EPS

N/A

Actual EPS

N/A

Financials

-128.69%Profit Margin

Unprofitable

2022

2023

2024

2025

8.5MRevenue

-10.94MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow APLM. It's not an investment recommendation.

Quantum Computing

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

Bristol-Myers Squibb

Bristol Myers Squibb is a leading biopharmaceutical company focusing on discovering, developing, and delivering innovative medicines that address serious diseases, including cancer, which competes directly with Apollomics' oncology pipeline.

Merck & Co., Inc. is a global healthcare company that offers cancer treatments and immunotherapies, directly competing with Apollomics' focus on developing novel therapeutics for oncology.

Pfizer is a global biopharmaceutical company with a broad range of drugs and vaccines, including treatments for cancer, making it a competitor in the oncology space against Apollomics.

Novartis AG is a multinational pharmaceutical company that produces a wide array of healthcare products, including innovative medicines for cancer, directly competing with Apollomics' cancer-focused therapies.

Roche Holding AG is a pioneer in healthcare, with a strong emphasis on oncology, making it a direct competitor to Apollomics through its comprehensive cancer treatment portfolio.

AstraZeneca PLC is a global, science-led biopharmaceutical business that focuses on the discovery, development, and commercialization of prescription medicines, including for cancer, which pits it against Apollomics in the oncology market.

Gilead Sciences

Gilead Sciences, Inc. is a biopharmaceutical company that discovers, develops, and commercializes innovative therapeutics in areas of unmet medical need, including oncology, competing with Apollomics' cancer treatments.

Amgen Inc. is one of the world's leading biotechnology companies, focusing on areas including oncology/hematology, which aligns it as a competitor to Apollomics in the cancer treatment arena.

Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc. is a biotechnology company that invents, develops, and commercializes medicines for the treatment of serious medical conditions, including cancer, making it a competitor to Apollomics.

Johnson & Johnson

Johnson & Johnson is a diversified healthcare giant that engages in the research and development, manufacture, and sale of a broad range of healthcare products, including oncology treatments, competing with Apollomics in the pharmaceutical and biotechnology market.

About

Apollomics Inc is an clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company programs include vebreltinib (APL-101), selective c-Met inhibitor for the treatment of non-small cell lung cancer and other tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia. Company has three new immuno-oncology product candidates: APL-501, APL-502 and APL-801 include mono-specific and bi-specific antibodies to fight against cancer.

Show more...

CEO

Hung-Wen Chen

Employees

15

Country

United States

ISIN

KYG0411D1236

Listings

0 Comments

Share your thoughts

FAQ

What is Apollomics stock price today?▼

The current price of APLM is $28.01 USD — it has increased by +2.43% in the past 24 hours. Watch Apollomics stock price performance more closely on the chart.

What is Apollomics stock ticker?▼

Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Apollomics stocks are traded under the ticker APLM.

Is Apollomics stock price growing?▼

APLM stock has risen by +5.3% compared to the previous week, the month change is a +59.37% rise, over the last year Apollomics has showed a +411.13% increase.

What is Apollomics market cap?▼

Today Apollomics has the market capitalization of 81.12M

When is the next Apollomics earnings date?▼

Apollomics is going to release the next earnings report on September 24, 2026.

What is Apollomics revenue for the last year?▼

Apollomics revenue for the last year amounts to 8.5M USD.

What is Apollomics net income for the last year?▼

APLM net income for the last year is -10.94M USD.

How many employees does Apollomics have?▼

As of September 04, 2026, the company has 15 employees.

In which sector is Apollomics located?▼

Apollomics operates in the Health & Wellness sector.

When did Apollomics complete a stock split?▼

The last stock split for Apollomics was on November 25, 2024 with a ratio of 1:100.

Where is Apollomics headquartered?▼

Apollomics is headquartered in Foster City, United States.